![Michael Dambach](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Michael E.
Dambach is currently Treasurer, Director & Vice President at Stromedix, Inc. and Treasurer & Vice President at Biogen, Inc. since 2010.
Former positions include Treasurer & Director at Bioverativ Therapeutics, Inc., Independent Director at BiomX, Inc. from 2023 to 2024, and Assistant Treasurer at Thermo Fisher Scientific, Inc. Education includes an MBA from Boston University and an undergraduate degree from the University of New Hampshire.
Michael Dambach active positions
| Companies | Position | Start |
|---|---|---|
| BIOGEN INC. | Treasurer | 01/01/2010 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Director/Board Member | - |
Former positions of Michael Dambach
| Companies | Position | End |
|---|---|---|
| BIOMX INC. | Director/Board Member | 15/03/2024 |
| THERMO FISHER SCIENTIFIC, INC. | Corporate Officer/Principal | - |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Director/Board Member | - |
Training of Michael Dambach
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
78
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of New Hampshire
 University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thermo Fisher Scientific, Inc.
 Thermo Fisher Scientific, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets analytical and environment monitoring instruments | Health Technology |
BiomX, Inc.
 BiomX, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin | Health Technology |
- Stock Market
- Insiders
- Michael Dambach
